Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
2021 Year in Review - Multiple Myeloma
Multiple Myeloma
18-Month Analysis of the Phase 3 ANDROMEDA Study of Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain Amyloidosis
Read More
Multiple Myeloma
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a BCMA x CD3 Bispecific Antibody, in RRMM
Read More
Multiple Myeloma
Updated Results of the KarMMa Trial of Idecabtagene Vicleucel CAR T-Cell Therapy in Patients with RRMM
Read More
Multiple Myeloma
Multiple Myeloma Year in Review Introduction
Read More
Multiple Myeloma
Updates from the Phase 3 ICARIA-MM Study of Isatuximab plus Pomalidomide/Low-Dose Dexamethasone versus Pomalidomide/Low-Dose Dexamethasone in RRMM
Read More
Multiple Myeloma
COVID-19 Vaccine Responsiveness in Patients with MM and Waldenström Macroglobulinemia
Read More
Multiple Myeloma
Iberdomide plus Dexamethasone and Daratumumab, Bortezomib, or Carfilzomib in Patients with RRMM
Read More
Multiple Myeloma
CARDAMON Trial Results of Carfilzomib Maintenance Following Transplantation or Carfilzomib/Cyclophosphamide/Dexamethasone Consolidation for NDMM
Read More
Multiple Myeloma
MAIA Trial Results of Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in NDMM
Read More
Multiple Myeloma
Updated Results from CARTITUDE-2 Trial of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Patients with Progressive MM After 1 to 3 Previous Lines of Therapy
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 26
